SGLT2 inhibitors lower chronic kidney disease risk in diabetes patients with higher DCSI: Study
Taiwan: The use of sodium-glucose cotransporter-2 inhibitors (SGLT2Is) significantly lowers the risk of chronic kidney disease (CKD) in type 2 diabetes patients with a higher DCSI (diabetes complications severity index), reveals a recent study published in the Journal of Nephrology.
Wei-Syun Hu from China Medical University in Taichung, Taiwan, and colleagues aimed to investigate the risk of CKD in type 2 diabetes patients with different scores of adapted DCSI who received SGLT2 inhibitors in a retrospective analysis. The DCSI quantifies the severity and presence of complications based on seven body systems or dimensions. It converts laboratory results and diagnostic codes into a 14-level metric quantifying the long-term diabetes effects on seven body systems.
The analysis included 113,449 patients with type 2 diabetes mellitus (T2DM) from the Taiwan NHIRD (National Health Insurance Research Database). They analyzed data collected from 107,440 patients demonstrating a change in DCSI score of < 1 per year, 2289 patients with a score change of > 2 per year, and 3720 patients with a change in score of 1 to 2 per year.
CKD risk throughout the follow-up period was assessed using Cox proportional hazard models. They were adjusted for age, sex, comorbidities, and medications of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, glucosidase inhibitors, dipeptidyl peptidase-4 inhibitors, biguanides, meglitinides, glucagon-like peptide-1 receptor agonists, insulin, a thiazolidinedione, and sulphonylurea.
The authors reported the following findings:
- The incidence of chronic kidney disease rose from 18.30 per 1000 person-years in patients with a score change of < 1 per year to 137.55 per 1000 person-years in patients with a score change of > 2 per year.
- Higher score change (> 2 per year) patients who received SGLT2 inhibitors had a lower risk of CKD development than patients who did not receive SGLT2Is.
"The use of sodium-glucose cotransporter-2 inhibitors is significantly linked with the decrease in the incidence of chronic kidney disease in T2DM with a higher diabetes complications severity index," the authors conclude.
About SGLT2 inhibitors
SGLT2 inhibitors are a class of prescription medication approved by the US FDA for use with exercise and diet to lower blood sugar in adults with type 2 diabetes. Medicines in the SGLT2 inhibitor class include dapagliflozin, canagliflozin, and empagliflozin. Their safety and efficacy have not been established in type 1 diabetes patients and are not approved by the FDA for use in these patients.
Reference:
Chen, TS., Yu, TS., Lin, CL. et al. Role of sodium-glucose cotransporter-2 inhibitors in risk of chronic kidney disease among patients with type 2 diabetes mellitus. J Nephrol (2022). https://doi.org/10.1007/s40620-022-01522-7
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.